Immunic announced results from interim safety analysis from ongoing phase 2 CALVID-1 trial of IMU-838 in patients with COVID-19
On Sept. 28, 2020, Immunic announced the results of a pre-planned interim safety analysis and a recruitment update…
-
-
Fourth large-scale COVID-19 vaccine trial began in the United States
On Sept. 23, 2020, a fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019…
-
Pascal Biosciences confirmed specific cannabinoids combat Coronavirus
On Sept. 23, 2020, Pascal Biosciences announced the Company had confirmed an earlier report that certain cannabinoids block…
-
Serum Institute initiated manufacturing of Codagenix’s intranasal live-attenuated COVID-19 vaccine candidate
On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s…
-
Roche launched new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
On Sept. 18, 2020, Roche announced the launch of its Elecsysﾮ Anti-SARS-CoV-2 S antibody test for markets accepting…
-
3CL protease inhibitor NLC-001 added to COVID-19-focused joint venture between Todos Medical and NLC Pharma
On Sept. 17, 2020, Todos Medical announced that NLC Pharma had added the dietary supplement NLC-001 to its…
-
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
-
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…
-
AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19
On Sept. 16, 2020, AIM ImmunoTech announced that recruitment had begun in Roswell Park Comprehensive Cancer Center’s Phase…
-
COVID-19 | FDA | Therapeutics
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
-
Laboratory testing of Brilacidin for COVID-19 in combination with remdesivir reduces viral load by nearly 100 percent
On Sept. 15, 2020, Innovation Pharma reported additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during…
-
FDA contracted with global partners to analyze coronavirus samples
On Sept. 15, 2020, the FDA awarded a $5.4 million research contract to the University of Liverpool and…
-
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
-
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
-
Genomic leaders collaborated to create Australia’s first national COVID-19 tracking system
On Sept. 14, 2020, Illumina announced that the Australian public health laboratories will aim to sequence the virus…
-
Meridian launched novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva
On Sept. 14, 2020, Meridian Bioscience announced the launch of a novel highly sensitive SARS-CoV-2 antibody pair to…
-
Transmission of COVID-19 outbreaks associated with child care facilities in Utah
On Sept. 11, 2020, the CDC reported that twelve children acquired COVID-19 in child care facilities. One parent…
-
Fosun Pharma announced novel Coronavirus (2019-nCoV) RT-PCR detection Kit included in WHO Emergency Use Listing
On Sept. 10, 2020, Shanghai Fosun Pharmaceutical announced that the Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit self-developed by…
-
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
T2 Biosystems received FDA Emergency Use Authorization for COVID-19 molecular diagnostic test
On Aug. 31, 2020, T2 Biosystems announced that it received FDA emergency use authorization (EUA) for its COVID-19…
-
Phase 3 clinical testing in the US of AstraZeneca COVID-19 vaccine candidate began
On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222…
-
Vir Biotechnology and GSK started phase 2/3 study of COVID-19 antibody treatment
On Aug. 31, 2020, Vir Biotechnology and GlaxoSmithKline announced that the first patient was dosed in a phase…
-
Biotechnology | Infectious Disease | Polio | Vaccine | WHO
Momentous milestone as Africa announced eradication of wild Poliovirus
On Aug. 25, 2020, the independent Africa Regional Certification Commission (ARCC) for Polio Eradication officially declared that the…
-
University of Oxford study described which cancer patients are more vulnerable to COVID-19
On Aug. 24, 2020, a published study led by the Universities of Oxford and Birmingham found that, compared…
-
COVID-19 drug candidate Brilacidin achieved a selectivity index among the highest reported
On Aug. 24, 2020, Innovation Pharma reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based…
-
La Jolla Institute for Immunology awarded $6.4 million for international efforts to beat COVID-19
On Aug. 20, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
-
Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrated robust protection in pre-clinical studies
On Jul. 30, 2020, Johnson & Johnson announced that its lead vaccine candidate protected against infection with SARS-CoV-2,…
